Compare HUDI & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUDI | SKYE |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 6.4M |
| IPO Year | 2019 | 2013 |
| Metric | HUDI | SKYE |
|---|---|---|
| Price | $0.52 | $0.80 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 49.9K | ★ 101.8K |
| Earning Date | 06-29-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.26 |
| 52 Week High | $1.67 | $11.04 |
| Indicator | HUDI | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 46.45 | 38.35 |
| Support Level | $0.45 | $0.50 |
| Resistance Level | $0.55 | $1.28 |
| Average True Range (ATR) | 0.06 | 0.20 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 51.53 | 55.23 |
Huadi International Group Co Ltd is a manufacturer of industrial stainless steel seamless pipes and tubes products. Its products are used in the oil & gas transmission, chemistry engineering, food processing, medical devices, aeronautics and astronautics, boiler, irrigation works construction, automobile and naval architecture, paper mill and mechanical industries. Company generates revenue from Sales of steel piping products. Products are exported to the United States, Mexico, Thailand, Singapore, Argentina, Taiwan, India, the Philippines, UAE and Canada. Geographically, majority revenue is generated from China.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.